Table 3 Associated factors with AKI within 28 days after intubation
N = 414 | AKI − | AKI + | P valuea |
|---|---|---|---|
N = 183 | N = 231 | ||
Age, mean ± SD | 61 ± 11 | 65 ± 10 | < 0.001 |
Gender, men, n (%) | 133 (73) | 187 (81) | 0.05 |
BMI, kg/m2, mean ± SD | 28.9 ± 5 | 30.4 ± 5 | 0.006 |
Hypertension, n (%) | 83 (45) | 151 (65) | < 0.001 |
Uncomplicated diabetes mellitus, n (%) | 34 (19) | 46 (20) | 0.73 |
Complicated diabetes mellitus, n (%) | 7 (4) | 27 (12) | 0.004 |
Chronic kidney disease, n (%) | 5 (3) | 28 (12) | < 0.001 |
Peripheral artery disease, n (%) | 4 (2) | 21 (9) | 0.003 |
History of myocardial infarction, n (%) | 10 (6) | 27 (12) | 0.04 |
Charlson Comorbidity Index, median [IQR] | 0 (0–1) | 1 (0–2) | < 0.001 |
= 0 | 92 (50) | 79 (34) | < 0.001 |
= 1 | 53 (29) | 54 (23) | |
≥ 2 | 38 (21) | 98 (42) | |
PEEP (cmH2O), mean ± SD | 11.3 ± 3 | 11.6 ± 3 | 0.32 |
Plateau pressure (cmH2O), mean ± SD | 23.5 ± 4 | 23.7 ± 4 | 0.60 |
N = 159/207 | |||
P/F, mean ± SD | 130 ± 54 | 124 ± 47 | 0.29 |
NO, n (%) | 21 (12) | 30 (13) | 0.64 |
Hydroxychloroquine, n (%) | 124 (68) | 137 (59) | 0.08 |
Lopinavir/ritonavir, n (%) | 30 (16) | 59 (26) | 0.03 |
Remdesivir, n (%) | 9 (5) | 12 (5) | 0.90 |
Corticosteroidsb, n (%) | 35 (21) | 50 (23) | 0.61 |
N = 221/171 | |||
Macrolides | 118 (65) | 141 (61) | 0.47 |
Co-infection | 19 (10) | 30 (13) | 0.42 |
Day 14 ventilatory mode | < 0.001 | ||
Death | 21 (12) | 73 (32) | |
Controlled or VV-ECMO | 64 (35) | 77 (33) | |
Pressure support | 40 (22) | 47 (20) | |
Extubated | 58 (32) | 34 (15) | |
Peak creatinine until day 28, median [IQR] | 80 [64–95] | 253 [147–436] | < 0.001 |
n = 181/205 | |||
Cardiac injury, n (%) | 10 (6) | 45 (20) | < 0.001 |
Alive at D28, n (%) | 145 (79) | 129 (56) | < 0.001 |
Day 28 VFD, median [IQR] | 8 (0–16) | 0 (0–2) | < 0.001 |
ICU survival, n (%) | 136 (75) | 104 (46) | < 0.001 |
N = 181/225 | |||